Patents by Inventor FRANZ KAPPEL
FRANZ KAPPEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11878098Abstract: A method includes: receiving measurements of a blood-related parameter corresponding to a patient undergoing hemodialysis; estimating a value of one or more hemodialysis treatment-related parameters by applying a vascular refill model based on the received measurements of the blood-related parameter, wherein the one or more hemodialysis treatment-related parameters are indicative of an effect of vascular refill on the patient caused by the hemodialysis; determining, based on the one or more estimated values of the one or more hemodialysis treatment-related parameters, a hemodialysis treatment-related operation; and facilitating performance of the treatment-related operation. The vascular refill model is a two-compartment model based on a first compartment corresponding to blood plasma in the patient's body, a second compartment based on interstitial fluid in the patient's body, and a semi-permeable membrane separating the first compartment and the second compartment.Type: GrantFiled: January 8, 2020Date of Patent: January 23, 2024Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Aurelio A. de los Reyes, V, Doris H. Fuertinger, Franz Kappel, Anna Meyring-Wosten, Stephan Thijssen, Peter Kotanko
-
Publication number: 20230352183Abstract: Described herein are computer systems and methods for generating, in silico, one or more virtual patients. The one or more virtual patients can be used, for example, to conduct a virtual clinical trial, such as to determine an efficacy of a therapy or medical device. The one or more virtual patients mathematically represent a physiological system in an actual patient for a health condition. Also, the one or more virtual patients can be used, for example, to determine an adverse effect from a therapy or any other deviation from a therapy, or compliance of a patient suffering from a health condition on a therapeutic protocol.Type: ApplicationFiled: April 1, 2022Publication date: November 2, 2023Applicant: Fresenius Medical Care Holdings, Inc.Inventors: Doris Fuertinger, Franz Kappel, Peter Kotanko, Stephan Thijssen
-
Publication number: 20220270719Abstract: Techniques and apparatus for generating, performing, and evaluating virtual clinical trials that include clinic modules to represent real-world operational aspects of trial entities are described. In one embodiment, for example, an apparatus may include at least one memory, and logic coupled to the at least one memory. The logic may be configured to generate a plurality of avatars configured to model a health condition associated with a population of patients, and to perform a virtual clinical trial to simulate a course of treatment for the plurality of avatars, the virtual clinical trial to include at least one clinic module associated with at least one event and a probability for the at least one event, the at least one event to model an operational aspect of an entity of the virtual clinical trial. Other embodiments are described.Type: ApplicationFiled: February 10, 2022Publication date: August 25, 2022Inventors: Doris H. Fuertinger, Alice Topping, Franz Kappel, Stephan Thijssen, Peter Kotanko
-
Patent number: 11295866Abstract: Described herein are computer systems and methods for generating, in silico, one or more virtual patients. The one or more virtual patients can be used, for example, to conduct a virtual clinical trial, such as to determine an efficacy of a therapy or medical device. The one or more virtual patients mathematically represent a physiological system in an actual patient for a health condition. Also, the one or more virtual patients can be used, for example, to determine an adverse effect from a therapy or any other deviation from a therapy, or compliance of a patient suffering from a health condition on a therapeutic protocol.Type: GrantFiled: December 18, 2015Date of Patent: April 5, 2022Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Doris Fuertinger, Franz Kappel, Peter Kotanko, Stephan Thijssen
-
Patent number: 11282590Abstract: Techniques and apparatus for generating, performing, and evaluating virtual clinical trials that include clinic modules to represent real-world operational aspects of trial entities are described. In one embodiment, for example, an apparatus may include at least one memory, and logic coupled to the at least one memory. The logic may be configured to generate a plurality of avatars configured to model a health condition associated with a population of patients, and to perform a virtual clinical trial to simulate a course of treatment for the plurality of avatars, the virtual clinical trial to include at least one clinic module associated with at least one event and a probability for the at least one event, the at least one event to model an operational aspect of an entity of the virtual clinical trial. Other embodiments are described.Type: GrantFiled: July 11, 2018Date of Patent: March 22, 2022Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Doris H. Fuertinger, Alice Topping, Franz Kappel, Stephan Thijssen, Peter Kotanko
-
Publication number: 20200139034Abstract: A method includes: receiving measurements of a blood-related parameter corresponding to a patient undergoing hemodialysis; estimating a value of one or more hemodialysis treatment-related parameters by applying a vascular refill model based on the received measurements of the blood-related parameter, wherein the one or more hemodialysis treatment-related parameters are indicative of an effect of vascular refill on the patient caused by the hemodialysis; determining, based on the one or more estimated values of the one or more hemodialysis treatment-related parameters, a hemodialysis treatment-related operation; and facilitating performance of the treatment-related operation. The vascular refill model is a two-compartment model based on a first compartment corresponding to blood plasma in the patient's body, a second compartment based on interstitial fluid in the patient's body, and a semi-permeable membrane separating the first compartment and the second compartment.Type: ApplicationFiled: January 8, 2020Publication date: May 7, 2020Inventors: Aurelio A. de los Reyes, V, Doris H. Fuertinger, Franz Kappel, Anna Meyring-Wosten, Stephan Thijssen, Peter Kotanko
-
Patent number: 10569000Abstract: A method includes: receiving measurements of a blood-related parameter corresponding to a patient undergoing hemodialysis; estimating a value of one or more hemodialysis treatment-related parameters by applying a vascular refill model based on the received measurements of the blood-related parameter, wherein the one or more hemodialysis treatment-related parameters are indicative of an effect of vascular refill on the patient caused by the hemodialysis; determining, based on the one or more estimated values of the one or more hemodialysis treatment-related parameters, a hemodialysis treatment-related operation; and facilitating performance of the treatment-related operation. The vascular refill model is a two-compartment model based on a first compartment corresponding to blood plasma in the patient's body, a second compartment based on interstitial fluid in the patient's body, and a semi-permeable membrane separating the first compartment and the second compartment.Type: GrantFiled: May 29, 2015Date of Patent: February 25, 2020Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Aurelio A. De los Reyes, V, Doris H. Fuertinger, Franz Kappel, Anna Meyring-Wosten, Stephan Thijssen, Peter Kotanko
-
Patent number: 10319478Abstract: A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, and employing the patient parameters and an initially selected EPO administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen.Type: GrantFiled: September 7, 2012Date of Patent: June 11, 2019Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Doris Helene Fuertinger, Franz Kappel, Peter Kotanko, Nathan W. Levin, Stephan Thijssen
-
Publication number: 20190019570Abstract: Techniques and apparatus for generating, performing, and evaluating virtual clinical trials that include clinic modules to represent real-world operational aspects of trial entities are described. In one embodiment, for example, an apparatus may include at least one memory, and logic coupled to the at least one memory. The logic may be configured to generate a plurality of avatars configured to model a health condition associated with a population of patients, and to perform a virtual clinical trial to simulate a course of treatment for the plurality of avatars, the virtual clinical trial to include at least one clinic module associated with at least one event and a probability for the at least one event, the at least one event to model an operational aspect of an entity of the virtual clinical trial. Other embodiments are described.Type: ApplicationFiled: July 11, 2018Publication date: January 17, 2019Inventors: Doris H. Fuertinger, Alice Topping, Franz Kappel
-
Publication number: 20170239409Abstract: A method includes: receiving measurements of a blood-related parameter corresponding to a patient undergoing hemodialysis; estimating a value of one or more hemodialysis treatment-related parameters by applying a vascular refill model based on the received measurements of the blood-related parameter, wherein the one or more hemodialysis treatment-related parameters are indicative of an effect of vascular refill on the patient caused by the hemodialysis; determining, based on the one or more estimated values of the one or more hemodialysis treatment-related parameters, a hemodialysis treatment-related operation; and facilitating performance of the treatment-related operation. The vascular refill model is a two-compartment model based on a first compartment corresponding to blood plasma in the patient's body, a second compartment based on interstitial fluid in the patient's body, and a semi-permeable membrane separating the first compartment and the second compartment.Type: ApplicationFiled: May 29, 2015Publication date: August 24, 2017Inventors: Aurelio A. De los Reyes, V, Doris H. Fuertinger, Franz Kappel, Anna Meyring-Wosten, Stephan Thijssen, Peter Kotanko
-
Patent number: 9679111Abstract: A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, the model including iron homeostasis, and employing the patient parameters and an initially selected ESA administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen. The method then includes administering ESA to the patient with an ESA administration regimen predicted to adjust the patient's hematocrit and/or hemoglobin concentration to the desired range at the predetermined time. The method can be implemented in a hemodialysis system.Type: GrantFiled: November 5, 2013Date of Patent: June 13, 2017Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Doris Helene Fuertinger, Franz Kappel, Peter Kotanko, Nathan W. Levin, Stephan Thijssen
-
Publication number: 20160180053Abstract: Described herein are computer systems and methods for generating, in silico, one or more virtual patients. The one or more virtual patients can be used, for example, to conduct a virtual clinical trial, such as to determine an efficacy of a therapy or medical device. The one or more virtual patients mathematically represent a physiological system in an actual patient for a health condition. Also, the one or more virtual patients can be used, for example, to determine an adverse effect from a therapy or any other deviation from a therapy, or compliance of a patient suffering from a health condition on a therapeutic protocol.Type: ApplicationFiled: December 18, 2015Publication date: June 23, 2016Inventors: Doris Fuertinger, Franz Kappel, Peter Kotanko, Stephan Thijssen
-
Publication number: 20140200181Abstract: A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, and employing the patient parameters and an initially selected EPO administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen.Type: ApplicationFiled: September 7, 2012Publication date: July 17, 2014Inventors: Doris Helene Fuertinger, Franz Kappel, Peter Kotanko, Nathan W. Levin, Stephan Thijssen
-
Publication number: 20140128791Abstract: A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, the model including iron homeostasis, and employing the patient parameters and an initially selected ESA administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen. The method then includes administering ESA to the patient with an ESA administration regimen predicted to adjust the patient's hematocrit and/or hemoglobin concentration to the desired range at the predetermined time. The method can be implemented in a hemodialysis system.Type: ApplicationFiled: November 5, 2013Publication date: May 8, 2014Applicant: Fresenius Medical Care Holdings, Inc.Inventors: DORIS HELENE FUERTINGER, FRANZ KAPPEL, PETER KOTANKO, NATHAN W. LEVIN, STEPHAN THIJSSEN